BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Braveheart Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 8, 2026
$19.21+0.50 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $142.19M
- P/E (TTM)
- –
- Dividend yield
- –
About Braveheart Bio
Pharmaceutical Preparations, SIC 2834
Braveheart Bio, Inc. is listed on Nasdaq under the ticker BRVE, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Braveheart Bio, Inc.
- Headquarters
- San Francisco, CA
- Address
- One Letterman Dr., Bldg. A, Ste. A4-300 94129
- Phone
- (415) 707-6312
- Website
- braveheart.bio
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- BRVE
- Exchange
- Nasdaq
- IPO date
- Aug 6, 2026
- Shares outstanding
- 90M, Sep 3, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2131524
- CUSIP
- 10567X101
- ISIN
- US10567X1019
- EIN
- 99-2981994
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Travis Murdoch | CEO and President, Director | 8,333,637 |
| Michele A. Anderson | Chief Development Officer | 332,161 |
| James Paul Rickey | Chief Financial Officer | 703,575 |
| Vineeta Agarwala | Director | 10,232,420 |
| Erez Chimovits | Director | 273,333 |
| Genesis GP LLC OrbiMed | Director | 273,333 |
| Capital GP IX LLC OrbiMed | Director | – |
| Advisors Llc Orbimed | Director | 1,102,739 |
| David Charles Lubner | Director | 55,555 |
| Jasper Bos | Director | – |
| Christopher Viehbacher | Director | 759,857 |
| Tim Lohoff | Director | – |
| David I. Malek | Director | 1,013,297 |
| Jason V. Coloma | Director | 1,100,456 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 6, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 3, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |